-
2026 MDA Clinical & Scientific Conference Opening Highlights the Power of Collaboration
Sharon Hesterlee, PhD, MDA President and CEO On March 9, Sharon Hesterlee, PhD, MDA President
-
PPMD and FED Announce 2026 Advocacy Leadership Awards Honoring Bipartisan Champions in Congress
PPMD, in partnership with the Foundation to Eradicate Duchenne (FED), is pleased to announce Representative
-
‘The Wonder Years’ were the ‘worry years’ before my MD diagnosis
I recently found myself rummaging through a very old collection of things from my childhood
-
Advocates Unite in Washington to Advance Duchenne and Becker Policy, Mark 25th Anniversary of MD-CARE Act
PPMD heads to Capitol Hill today with a group of more than 120 Duchenne and
-
MDA 2026: More dietary protein linked to better lower limb function in MD
Eating more protein was associated with better lower limb function and a higher quality of
-
Clinical Study Alert: Phase 1 Study of MyoPAXon in Boys with DMD
Researchers at the University of Minnesota are seeking boys with Duchenne muscular dystrophy (DMD) to participate
-
Brogidirsen (NS-089/NCNP-02) 4.5-Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy (DMD) Presented at 2026 MDA Clinical & Scientific Conference.
NS Pharma, Inc. presented 4.5-year safety and efficacy data based on the open-label extension study
-
Dyne reports cardiopulmonary benefits in Duchenne trial of z-rostudirsen in individuals amenable to skipping exon 51
As an early investor in Dyne Therapeutics, CureDuchenne is happy to share that new analyses
-
Long-term AGAMREE data indicates continued effectiveness with clinically meaningful safety advantages over classic corticosteroids
Santhera Pharmaceuticals announced results from the ongoing Guardian study in Duchenne, and showed that AGAMREE
-
In Case You Missed It…
Quest Media is an innovative, adaptive lifestyle platform from MDA. With the power of this
